In COVID-19 clinical update #53, Daniel Griffin reviews underreporting of infections and long term disease in children, a blood test for T cells, results of phase 3 trials for monoclonal antibodies, preliminary findings on an oral antiviral, clinical trial of ivermectin, and recommendations for upcoming gatherings.
Matt Frieman returns to TWiV to discuss the COVID-19 pandemic from the point of view of a coronavirologist, including his work with Novavax on their spike protein-based vaccine.
TWiV notes the passing of Mavis Agbandje-McKenna, and reviews data on maximizing fit for cloth and medical procedure masks, SARS-CoV-2 total and subgenomic viral load in hospitalized patients, and effect of changes in spike protein on efficacy in a mouse model of infection.
In COVID-19 clinical update #52, Daniel Griffin reviews differences in attack rates between children and adults, J&J vaccine phase III data, G6PD deficiency and vaccines, NIH halts convalescent plasma trial, dexamethasone in hospitalized patients, data on tocilizumab, and long COVID in children.
In COVID-19 clinical update #51, Daniel Griffin reviews use of two masks, effectiveness of testing in nursing homes, updates on vaccines, use of nonsteroidal anti-inflammatory drugs, little effect of vitamin D and remdesivir in clinical studies, and a long COVID research initiative from NIH.
Ginger Campbell joins TWiV to discuss palliative care for COVID-19 patients, and how to approach the disease from a goals of care perspective.
The entire TWiV team assembles to discuss resurgence of COVID-19 in Manaus, Brazil, discovery of SARS-CoV-2 related viruses in bats in Southeast Asia, and increased Ct values after administration of mRNA vaccine.
In COVID-19 clinical update #50, Daniel Griffin discusses CDC guidance on school opening, decreased viral load after vaccination, randomized clinical trial of vitamin D treatment, a study of zinc plus vitamin C, anticoagulation therapy effect on mortality, and multi system inflammatory phase in children.
Paul Offit joins TWiV to discuss all things vaccine, including how COVID-19 vaccine development was accelerated, whether the vaccines are safe and efficacious, the difference between an EUA and a licensed vaccine, sterilizing immunity, herd immunity, and much more.
In COVID-19 clinical update #49, Daniel Griffin discusses CDC guidelines on mask use, drop in test frequency in the US, resurgence of COVID-19 in Brazil, possible impact of Pfizer vaccine on viral load, EUA for bamlanivimab and etesevimab administered together, and preliminary results of Tocilizumab in hospitalized patients.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.